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Abstract
Sepsis, with a persistently high 90-day mortality of about 46%, is the third most frequent
cause of death in intensive care units worldwide. Further understanding of the inflammatory
signaling pathways occurring in sepsis is important for new efficient treatment options. Key
regulator of the inflammatory response is the transcription factor NFκB. As we have recently
shown, the -94 Ins/Del NFKB1 promoter polymorphism influences sepsis mortality. How-
ever, a molecular explanation is still missing. Thus, promoter activity might be varying
depending on the NFKB1 genotype, explaining the genotype dependent mortality from sep-
sis, and one likely mechanism is the degree of promoter methylation. Therefore, we tested
the hypothesis that NFκBmRNA expression is regulated by promoter methylation in human
cell lines and primary immune cell cultures. First, we examined the methylation of the
NFKB1 promoter in U937, REH and HL-60 cells. In the promoter region of nt+99/+229 meth-
ylation in all analyzed cell lines was below 1%. Following incubation with bacterial cell wall
components, no significant changes in the frequency of promoter methylation in U937 and
REH cells were measured and the methylation frequency was under 1%. However, NFκB1
mRNA expression was two-fold increased in U937 cells after 24 h incubation with LPS. By
contrast, demethylation by 5-Aza-20-deoxycytidine incubation enhanced NFκB1 expression
significantly. In addition, we analyzed NFKB1 promoter methylation in primary cells from
healthy volunteers depending on the NFKB1–94 Ins/Del genotype. Methylation in the
promoter region from nt+402 to nt+99 was below 1%. Genotype dependent differences
occurred in neutrophil cells, where DD-genotype was significantly more methylated com-
pared to II genotype at nt+284/+402. Besides in the promoter region from nt-227/-8 in ID-
genotypes methylation of neutrophils was significantly decreased compared to lymphocytes
and in II-genotypes methylation in neutrophils was significantly decreased compared to lym-
phocytes and monocytes. In addition, CHART-PCR showed that the hypomethylated pro-
moter regions are highly accessible. Therefore we assume that the demethylated regions
are very important for NFKB1 promoter activity.
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Background
Sepsis is one of the most frequent causes of death in intensive care units worldwide and there-
fore a global problem [1]. It is characterized by the host’s systemic inflammatory response to
infection, but the pathophysiological changes occurring in sepsis are not fully understood yet
[2]. During sepsis the immune system is confronted with lots of extrinsic and intrinsic factors
which cause changes of the basal state of responsiveness of lots of immune cells [3]. It is known
that genetic variations could influence the outcome in sepsis [4]. A potential candidate for such
variations is the gene encoding NFκB (Gene ID: 4790), since the NFκB-coupled pathway is
known to amplify and perpetuate inflammatory mechanisms prevailing in sepsis [5]. We have
already shown that the D allele of the functional NFKB1 insertion/deletion (−94ins/delATTG)
(rs28362491) polymorphism is associated with increased 30-day mortality in patients with
severe sepsis [4,6,7]. Furthermore, NFκB expression differs between insertion and deletion
allele carriers [4]. Unfortunately, the molecular mechanisms leading to differences in NFκB
expression still remain unclear. It is known that epigenetic mechanisms, such as histone modi-
fications and DNA methylation, play a role in the control of the immune system [8]. DNA
methyl transferases (DNMTs) catalyze DNAmethylation, silencing the particular gene expres-
sion. Therefore, a likely mechanism regulating NFκB expression in septic patients is DNA
methylation. Due to the aforementioned facts, we tested the hypotheses that 1) NFκB mRNA
expression is regulated by DNA methylation in immune cells, 2) NFKB1 promoter methylation
affects NFκB mRNA expression, 3) NFKB1 promoter methylation is altered by inflammatory
stimuli, and 4) the NFΚB1 insertion/deletion (−94ins/delATTG) polymorphism is associated
with NFκB promoter methylation.
Materials and Methods
Cell isolation from healthy donors
Neutrophil cells, lymphocytes and monocytes were isolated from 80 ml of venous blood
obtained from healthy donors after ethics committee approval (Ethics Committee of the Ruhr
University Bochum, Bochum, Germany, Reg.-No.: 4899–14) and written informed consent. In
brief, cells were separated using Polymorphprep density gradient centrifugation (Progen Bio-
technik, Mannheim, Germany). The upper compartment containing PBMCs and the lower
compartment containing neutrophil cells were collected and washed with PBS. Monocytes
were isolated using the Monocyte Isolation Kit II, human (Miltenyi, Bergisch-Gladbach, Ger-
many). DNA from neutrophils, monocytes and lymphocytes was extracted directly. In addition
Monocytes and lymphocytes were stimulated with LPS (1μg/ml) for 24 h or left unstimulated.
Cells were lysed and DNA and RNA was extracted using the QIAamp DNA blood mini kit
(Qiagen, Hilden, Germany) and RNeasy MiniKit (Qiagen, Hilden, Germany).
Genotyping of healthy volunteers
Genotyping was performed as described before [6].
Cell culture experiments with U937, HL-60, Jurkat and REH
We used the cell lines U937, Hl-60, Jurkat and REH to investigate the methylation of the
NFκB1 promoter gene in immune cells. The cells (U937, HL-60, Jurkat) were purchased from
DSMZ (Leipzig, Germany) and from CLS (Eppelheim, Germany; (REH)). Firstly, we ana-
lyzed AQP5 promoter methylation after incubation with the DNA-demethylation agent
5-Aza-2'-deoxycytidin (ADC, Sigma-Aldrich, A3656). For this purpose, cells were incubated
with 50 μM 5-Aza-20-deoxycytidine (ADC) for three days and, after culture medium change,
NFKB1 Promoter and Methylation
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with 10 μMADC for an additional three days. Our previous studies indicated that a seven
day incubation period is required for efficient demethylation of promoters [9]. In addition,
we investigated the impact of bacterial cell wall components on NFKB1 promoter methyla-
tion. The cells were cultured in RPMI 1640 medium, supplemented with 10% FCS, penicillin
(100 U/ml) and streptomycin (100 μg/ml). Cell cultures were split twice a week to maintain a
cell density of about 106 cells/ml. Cells in early passages (< 25) were used for all experiments,
seeded in 6-well culture dishes and stimulated with either 1 μg/ml lipopolysaccharide (LPS),
10 μg/ml lipoteichoic acid (LTA) (Sigma-Aldrich Taufkirchen, Germany) or were left unsti-
mulated (control).
Cells were lysed either 24 h and 48 h after stimulation and DNA and RNA was extracted
using the QIAamp DNA blood mini kit (Qiagen, Hilden, Germany) and RNeasy MiniKit (Qia-
gen, Hilden, Germany).
Methylated and unmethylated control DNA
The Cells-to-CpG™Methylated & Unmethylated gDNA Control Kit (applied Biosystems,
Darmstadt, Germany) was utilized to examine primer specificity. DNA was bisulfite converted
with the EZ DNAMethylation-Gold™ Kit (Zymo research, Irvine, CA USA), following the
manufacturer’s instructions. Primers (Table 1 and Fig 1) were designed using MethPrimer [10]
and used for gradient PCR and products were analyzed using agarose gel electrophoresis.
Methylation analysis was performed by real-time PCR [11]. The real-time PCR reaction was
performed using GoTaq1 qPCRMaster Mix (Madison, WI, USA). A DNA dilution series for
methylated and unmethylated DNA was performed and a standard curve was calculated by
determining DeltaCt(Ct(U)- Ct(M)) for each primer pair. According to the standard curves,
Table 1. Primer pairs for CHART-PCR and Methylation-specific PCR.
Primer name Sequence Product size (bp)
NFKB-779_SE GCC TGG TGA GGA CCT GAT TAC 278
NFKB-501_AS TGATCTGGCAGAGGGGAGTT
NFKB -596_SE AGT GCC CAG CAC TAA AGC AG 537
NFKB-59_AS TAG GGA AGC CCC CAG GAA G
NFKB-216_SE CTT GGA TCC ATG CCG ACC C 411
NFKB+215_AS CCA CTG ACG TCG AGA GAG C
NFKB-170_SE GCTATGGACCGCATGACTCT 523
NFKB+353_AS ACG GGA AGG GCA GGG GAA
Left M1 primer GTAGGAAGAGGAGGTTTCGTTATC 119
Right M1 primer ACCGATAACTACGTACAAACCGA
Left U1 primer GGTAGGAAGAGGAGGTTTTGTTATT 122
Right U1 primer AAACCAATAACTACATACAAACCAA
Left M2 primer TATTTGGTATGTTTGGATTTATGTC 219
Right M2 primer AACTCTAACTTCCTAACAAAACGCT
Left U2 primer TTGGTATGTTTGGATTTATGTTGA 217
Right U2 primer AAACTCTAACTTCCTAACAAAACACT
Left M3 primer GCGTATAGCGTTTTTAGAAGTGC 130
Right M3 primer TAACTAAAAATTCCCACTAACGTCG
Left U3 primer GGGTGTATAGTGTTTTTAGAAGTGTG 130
Right U3 primer ACTAAAAATTCCCACTAACATCAAA
doi:10.1371/journal.pone.0156702.t001
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the methylation was quantified using the following formulas:
Methylated DNA þ99=þ 229ð Þ %½ 
¼ 74; 67100ð74; 67þ ðð100 74; 67ÞEXPð1000; 010774DeltaCTÞÞÞ
Methylated DNA þ284=þ 402ð Þ y
¼ 92; 61100ð92; 61þ ðð100 92; 61ÞEXPð1000; 015886DeltaCTÞÞÞ
Methylated DNA 227= 8ð Þ y
¼ 22; 256100ð22; 256þ ðð100 22; 252ÞEXPð1000; 018369DeltaCTÞÞÞ
Bisulfite treatment of DNA and methylation analysis
Bisulfide conversion of isolated DNA was performed with the EZ DNAMethylation-Gold™ Kit
(Zymo research, Irvine, CA USA) following the manufacturer’s instructions. Methylation-spe-
cific PCR was performed, as described previously[11,12]. The following primer pairs were uti-
lized to amplify methylated (M) and unmethylated (U) DNA (Table 1).
Methylation was calculated using the formulas described above.
Fig 1. Graphic view showing primers and sequence features such as GC percent, CpG islands, and CpG site derived fromMethPrimer [10]
nucleotide numbers base on transcription initiation site [16] a) graphic view of the NFKB1 Promoter sequence from nt-800 to nt+600; CpG
dinucleotides are indicated as bars b) graphical view of primers utilized for CHART-PCR, c) graphical view of primers utilized for methylation
specific PCR.
doi:10.1371/journal.pone.0156702.g001
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Real-time PCR for expression analysis
Total RNA from cells was extracted as described above and 1 μg RNA was used to synthesize
cDNA. The following primers were used for NFκB1 real-time PCR: (forward primer) 5'-
CGCCGCTTAGGAGGGAGAG -3', (reverse primer) 5'- TGAAGGTATGGGCCATCTGC -3',
resulting in a 204 bp fragment. Primers for the housekeeping gene actin were used as described
[13]. The real-time PCR reaction was performed using GoTaq1 qPCRMaster Mix (Madison,
WI, USA). A cDNA dilution series for NFκB confirmed a PCR efficiency> 95%, which was
comparable to the efficiency of actin. Relative NFκBmRNA expression was measured by two-
step real-time PCR with actin as an internal control and calculated as 2−[Ct(NFκB)−Ct(β−Actin)].
Chromatin Accessibility Assay (CHART)
U937, REH and HL-60 cells were pelleted by centrifugation at 400 g for 5 min. Cells (5 × 106
cells/sample) were washed once in ice-cold PBS. The cell pellet was resuspended in 1 ml ice-
cold Nonidet P-40 lysis buffer (10 mM Tris (pH 7.4), 10 mM NaCl, 3 mMMgCl2, 0.5% Noni-
det P-40, 0.15 mM spermine, and 0.5 mM spermidine) and incubated on ice for 10 min The
suspension was centrifuged at 3000 rpm for 5 min to pellet the nuclei. The nuclei were subse-
quently washed in the respective digestion buffer (without CaCl2). DNase I, micrococcal nucle-
ase (MNase, NEB, Frankfurt, Germany), was performed as previously described [14,15]. A
control without the MNase was included for all samples. The genomic DNA was isolated using
a QIAamp blood kit (Qiagen, Hilden, Germany). After DNA isolation DNA concentration was
adjusted to 10 ng/μl. Subsequent PCR was carried out using OneTaq1 Quick-Load 2X Master
Mix (NEB, Frankfurt, Germany) supplemented with 5% DMSO (Roth, Karlsruhe, Germany)
using specific primers (Table 1 and Fig 1).
In silico analysis
Analysis of putative transcription factor binding sites was facilitated using MathInspector
(Genomatix software suite).
Statistical analysis
Continuous parametric variables are presented as means ± standard error of the mean (SEM).
The values were compared by unpaired t-test. All statistical analyses were carried out using
GraphPad Prism 6 (GraphPad Software, La Jolla, USA). Differences were regarded as statisti-
cally significant with an a priori alpha error p of less than 0.05.
Results
Using MethPrimer [10] one CpG island could be detected in the NFKB1 promoter spanning
the region of nt-200 to nt+600 (Fig 1a). Primers for CHART (Fig 1b) and Methylation specific-
PCR (Fig 1c) are pictured. All nucleotide numbers depend on the main transcription initiation
site identified by Ten et al. [16].
Three standard curves were established for quantification of the fraction of methylated mol-
ecules within the primer-binding sequences of the NFKB1 promoter for the three different pro-
moter regions (nt+99/229, nt+284/402, nt-227/-8). Standard curve for the region nt+284/402 is
displayed (Fig 2). Reliability of reproducibility was high with a correlation coefficient r = 0.99
between two independent experiments.
First we analyzed the methylation of the NFKB1 promoter in three different cell lines (REH,
HL-60 and U937). The methylation of the promoter region from nt+284 to nt+402 was
between 1% and 4% in the analyzed cell lines and there was no significant difference between
NFKB1 Promoter and Methylation
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the cell lines. In the promoter region of nt+99/+229 methylation in all analyzed cell lines was
below 1%. In line with that methylation of U937 and REH cells was below 1% in the NFKB1
promoter of nt-221/-8, where only HL-60 cells showed a methylation of 3% (Fig 3, all p>0.05).
Testing the hypothesis that NFκB1 expression is regulated by promoter methylation in
immune cells, we examined the influence of inflammatory stimuli on the frequency of NFκB1
Fig 2. standard curve derived from the CT valuesmeasured for the nt+284/402 NFKB1 promoter region. The CT values were measured in a
dilution series with defined portions of methylated and unmethylated DNA (red values). A standard curve was calculated from these values (blue values).
doi:10.1371/journal.pone.0156702.g002
Fig 3. Methylation of the NFKB1 promoter in three different cell lines. Three different promoter regions were analyzed: nt+284/+402, nt+99/+229, nt-
227/-8 (n = 3). A methylated (M-DNA) and unmethylated (U-DNA) was used as control.
doi:10.1371/journal.pone.0156702.g003
NFKB1 Promoter and Methylation
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promoter methylation in the region of nt+99/+229. The mean values of methylation in the
experiments all showed low rates of NFκB1 promoter methylation ranging from 0.02 to 0.08%
methylated molecules with and also without inflammatory stimulation (Table 2) in cell lines.
We isolated neutrophil cells, lymphocytes and monocytes from whole blood of twelve vol-
untary, healthy individuals to collateralize these results in primary human cells.
Analysis of the methylation status dependent on NFKB1–94 (Ins/Del) genotype was per-
formed in three different cell types and for three different NFKB1 promoter regions. Methyla-
tion of the promoter region from nt+402 to +99 was below 1% in all analyzed cells. In contrast
methylation from nt-227 to -8 was between 5% and 10% in the analyzed cells (Fig 4). Genotype
dependent differences occurred in neutrophil cells, where DD-genotype was significantly more
methylated compared to II genotype at nt+284/+402 (p = 0.0094). In addition in the promoter
region surrounding the NFKB1 polymorphism from nt-227 to -8 no difference in methylation
between cells was detected in DD-genotypes, whereas in ID-genotypes methylation of neutro-
phils was significantly decreased compared to lymphocytes (p = 0.0151) and in II-genotypes
methylation in neutrophils was significantly decreased compared to lymphocytes (p = 0.0362)
and monocytes (p = 0.0053) (Fig 4).
In addition NFKB1 promoter (nt+99/+229) was examined after LPS of LTA incubation.
Neutrophils, lymphocytes and monocytes of the three NFΚB1 insertion/deletion (−94ins/
delATTG) polymorphism genotypes did not show any significant differences in the methyla-
tion density either with or without inflammatory stimulation (p>0.05). The range of methyl-
ated molecules ranged from 0.05 to 0.11% in monocytes without stimulation, from 0.05 to
0.11% in neutrophils without stimulation and from 0.07 to 0.13% in lymphocytes without stim-
ulation (all p>0.05). Thus, there was no significant difference between the genotypes. After 24
h of LPS-stimulation, monocytes (p = 0.51) and lymphocytes (p = 0.34) did not change the
fraction of methylated promoter molecules significantly. Even after 48 h of LPS-stimulation,
there was no significant change in methylation density compared to unstimulated cells (mono-
cytes p = 0.39; lymphocytes p = 0.44, Table 3).
Both Gram-negative (LPS) and -positive (LTA) stimulation showed an impact on the
NFκB1 expression. The NFκB1/β-actin ratio in U937 cells showed a two-fold increase in
NFκB1 expression following the 24 h incubation with Gram-negative or -positive substance
(Fig 5, p = 0.047 unstimulated vs LPS-stimulated; p = 0.1 unstimulated vs LTA-stimulated).
Finding no significant changes in the methylation status of NFκB1 promoter in cell lines
after LPS, we tested whether the insertion of 5-desoxy-aza-cytidine (ADC), which replaces cyti-
dine in the genomic DNA and cannot be methylated by DNMTs, has the potential to increase
the NFκB1 expression. After seven days, we detected a two-fold increase in the ratio of NFκB1/
ß-actin expression after ADC incubation in U937 cells (Fig 6, mean of three independent
Table 2. Methylation of the +99/+229NFKB1 promoter region of different cell lines of human lymphocyte cells. The cells were stimulated with LPS
(1 μg/ml), 10 μg/ml LTA or left unstimulated, and DNA was extracted for methylation analysis (n = 2).
1. Measurement 2. Measurement
DELTA CT (U-M) Methylation [%] DELTA CT (U-M) Methylation [%]
REH 24 h LPS -11.345 0.14 -13.895 0.01
REH 24 h LTA -12.685 0.03 -14.595 0.00
REH 24 h KO -12.03 0.07 -12.35 0.05
U937 24 h LPS -13.81 0.01 -12.025 0.07
U937 24 h LTA -13.335 0.02 -11.365 0.14
U937 24 h KO -12.365 0.05 -12.96 0.03
doi:10.1371/journal.pone.0156702.t002
NFKB1 Promoter and Methylation
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experiments, p = 0.0069). Thus the demethylation of the cellular DNA influences the NFκB1
mRNA expression.
To conclude we analyzed the accessibility of the NFKB1 promoter by CHART-PCR. Pro-
moter region of nt+779/+501 was mainly inaccessible for MNase digestion as shown by PCR
Fig 4. methylation of the NFKB1 promoter in different immune cells depending on the NFKB1–94 (Ins/
Del) genotype (n = 12). Three different promoter regions were analyzed. NFKB1 promoter was
unmethylated (<1%) from nt+402/+99. From nt-227 to -8 the methylation was about 5% to 10%.
doi:10.1371/journal.pone.0156702.g004
NFKB1 Promoter and Methylation
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(Fig 7a) in all analyzed cell lines. In REH and U937 cells DNA became accessible from nt-216
(Fig 7b, 7c and 7d) and DNA from HL-60 cells was accessible from nt-170 (Fig 7d).
Discussion
In this study, we analyzed the NFKB1–94(Ins/Del) genotype dependent promoter methylation.
Thus, we are the first to show, that NFKB1 promoter methylation differs in II and DD geno-
types in neutrophil cells. Therefore genotype dependent differences in patients outcome and
the inflammatory response may result from promoter methylation in immune cells [17,18].
We further showed that the methylation of the NFKB1 promoter methylation is reduced in
neutrophil cells from II and ID genotypes compared to lymphocytes and monocytes. In con-
trast incubation with inflammatory stimuli of both a human lymphoid cell line (REH) and a
human monocytic cell line (U937) and primary human blood cells did not show any significant
differences in the methylation density of the NFKB1 promoter. Another important result of
our study is, that the NFKB1 promoter region from nt+402/+94 is hypomethylated as it was
below 1% in primary samples. In addition this promoter region was shown to be highly accessi-
ble as it was shown with CHART-PCR. In line with that the promoter region containing the
polymorphism was highly accessible and methylation was below 10% in the analyzed samples.
Therefore these regions might play an important role in NFκB expression.
Table 3. Methylation of the +99/+229 NFKB1 promoter region of different blood cells isolated from healthy volunteers. Cells were isolated from fresh
EDTA blood. They were then stimulated with LPS (1 μg/ml) or left unstimulated and DNA was extracted for methylation analysis (n = 3).
Methylation [%] Proband 1 Proband 2 Proband 3
(ID) (II) (DD)
Monocytes 0.05 0.11 0.06
Monocytes after 24 h LPS 0.06 0.06 0.06
Monocyts after 48 h LPS 0.03 0.21
Neutrophils 0.09 0.05 0.11
Lymphocytes 0.07 0.07 0.13
Lymphocytes after 24 h LPS 0.06 0.04 0.09
Lymphocytes after 48 h LPS 0.09 0.10
doi:10.1371/journal.pone.0156702.t003
Fig 5. NFκB expression in U937 cells 24 h after stimulation with 1 μg/ml LPS or 10 μg/ml LTA (n = 4).
doi:10.1371/journal.pone.0156702.g005
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The hypomethylation in the NFKB1 promoter might be reasonable because NFκB1 is con-
secutively expressed in immune cells. NFκB1 is present in cells in an inactive state and do not
require new protein synthesis in order to become activated. Furthermore, the NFκB1 is not
only involved in inflammatory processes, but also in several other cellular signaling pathways
[19–21]. Therefore, downregulation of NFκB1mRNA expression by methylation might impact
on cellular pathways, which regulate expression of genes involved in embryo or cell lineage
development or cell cycle progression, which are required for survival.
In contrast to our hypothesis that NFκB is not regulated by NFΚB1 promoter methylation,
we found that demethylation of DNA with the demethylation agent ADC let to an increased
amount of NFκB expression. Therefore we can assume that demethylation with ADCmight
further demethylate the NFKB1 promoter region from nt-227/-8, which might further increase
NFKB1 promoter activity. Additionally, this might be due to upregulation of several other fac-
tors, which are affected by demethylation as well.
Thus it need to be questioned whether other genes involved in the LPS signaling pathway in
immune cells are regulated by methylation. Studying the current literature, we found that some
transcription factors, which are induced after LPS incubation in immune cells [22] are indeed
regulated by methylation. As an example, SRF (serum response factor) and Elk1 (member of
the ETS oncogene family) are regulated by promoter methylation (Table 4 [23]), while other
genes, such as the transcription factor CREB (cAMP response element binding protein), are
not regulated by methylation of its promoter (Table 4). In addition, there are numerous hints
that important inflammatory genes, such as IL-6, IL-8 Tnf-α and the Toll-like receptors
(TLRs) 2 and 4, are regulated by methylation of their promoters (Table 4 [24–27]).
Fig 6. NFκB expression in U937 cells. Cells were left unstimulated (U937) or incubated with a final concentration of 10 μMADC for seven
days. (n = 4).
doi:10.1371/journal.pone.0156702.g006
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Fig 7. chromatin accessibility (CHART) of different regions of the NFKB1 promoter.Chromatin from different cell lines was incubated with MNase
(+) or left untreated (-) and DNA was extracted. PCR of different NFKB1 promoter regions as performed.
doi:10.1371/journal.pone.0156702.g007
Table 4. Overview of literature of regulation bymethylation of important transcription factors and inflammatory genes.
Gene/protein name Regulated by methylation Reference
ELK1 Yes, downregulated in cancer [23]
SRF Yes, downregulated in cancer [23]
CREB To the best of our knowledge, there are no data available
IL-6 Promoter demethylation after ADC, LPS has no additional effect on demethylation,
one position: nt-1099 is less methylated in PBMCs of patients with rheumatoid
arthritis
[29,30]
IL-8 7.0-fold increased expression after LPS with ADC-TSA (trichostatin A) treatment [24]
IL-6 2.5-fold increased expression after LPS with ADC-TSA (trichostatin A) treatment [24]
TNF-α 1.6-fold increased expression after LPS with ADC-TSA (trichostatin A) treatment [24]
TLR-2 Hypomethylation is associated with increased proinflammatory response [25]
TLR-4 TLR-4 hypermethylation causes low response to LPS [26]
TLR-2, TLR-4, lipopolysaccharide-binding protein
(LBP) and haptoglobin (HP)
Promoters are opened after LPS, which may be caused by demethylation [27]
doi:10.1371/journal.pone.0156702.t004
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In contrast to these findings in literature, NFκB1 demethylation was not responsible for
increased activation of NFκB1 after an inflammatory stimulus such as LPS [4,22]. In this study,
we now could demonstrate that LPS did not alter NFKB1 promoter methylation. This is not
surprising, because as mentioned above NFκB1 is present in cells in an inactive state and do
not require new protein synthesis in order to become activated. The rapid activation of NFκB1
after LPS is facilitated by the nuclear translocation of NFκB dimers after degradation of the
inactivator IKKB [22].
We can only speculate about the meaning of the lack of NFκB1methylation, which is not
altered after LPS. Analyzing the hypomethylated NFκB1 promoter sequence, we found several
putative binding sites for SP-1, CREB and NFκB1 in this promoter region. Therefore, rapid
activation and ubiquitary expression of NFκB1 might be facilitated by hypomethylation and
binding of these factors.
In summary, we show for the first time that the NFκB1 promoter is hypomethylated and
that methylation of neutrophils depends on NFKB1–94 (Ins/Del) genotype. This might be
important for novel therapeutic approaches which use demethylation of other genes. A novel
study could show that aberrant DNAmethylation in lung tissue samples from rats is associated
with altered outcome of acute respiratory distress syndrome [28]. Therefore, it might be benefi-
cial for therapies with DNA-methylation-altering pharmaceuticals that the NFκB signaling
pathway is not altered by this therapeutic.
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